Lentiviral vector may deliver sustained antiangiogenic therapy

NEW YORK — Advances in gene therapies for ocular disease have reached a point where it may be possible for therapeutic effects to be sustained for years, Timothy Stout, MD, said in the Verhoeff Lecture at the American Ophthalmological Society meeting here. To illustrate the advance, Stout recounted experiments underway in nonhuman primates in which the retina of the right eye was injected with plain saline, with a lentivirus that contained a marker gene, or with a lentivirus that contained two antiangiogenic genes — in this case, endostatin and angiostatin. (Read more...)

Full Story →